Moves strengthen existing analytical and bioanalytical drug development service offering
Supports qNMR facility in providing reference material characterisation and quantitative measurement research for customers
Innovative genomics solution addresses issues of increasing throughput and achieving high data quality
Achievement underlines expertise of Berlin sequencing team
Funding helps develop screening and validation tools for functional genomics, cell line engineering and synthetic biology
PSI products complement existing genomics offering
LGC operates out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India.